⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16285438 | 0.78 | — | — | |
| SCHEMBL2106440 | 0.77 | — | — | |
| SCHEMBL14447772 | 0.76 | LMNA (0.44) | — | |
| SCHEMBL3660629 | 0.74 | LMNA (0.63) | — | |
| SCHEMBL15778117 | 0.74 | MCL1 (0.32) | — | |
| SCHEMBL6773592 | 0.73 | — | — | |
| SCHEMBL146293 | 0.73 | — | — | |
| Alcohol SCHEMBL27646080 | 0.73 | — | — | |
| SCHEMBL9329 | 0.71 | — | — | |
| SCHEMBL96317 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113710664-B | JAK1 selective kinase inhibitors | 迪哲(江苏)医药股份有限公司 | 2024-01-26 | — | — | CN | claimed |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-10-26 | — | — | US | claimed |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-03-21 | — | — | US | claimed |
| CN-115835908-A | Bicyclic heterocycles as FGFR inhibitors | 因赛特公司 | 2023-03-21 | — | — | CN | claimed |
| CN-111992247-B | Preparation method of graft catalyst for continuous catalytic synthesis of isobutyl isobutyrate | 润泰化学（泰兴）有限公司 | 2022-11-22 | — | — | CN | claimed |
| US-11480502-B2 | Method and composition for optical clearing of tissues | United States of America, as represented by the Secretary, Department of Heatlth and Human Service (US) | 2022-10-25 | — | — | US | claimed |
| EP-4045151-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2022-08-24 | — | — | EP | claimed |
| CN-114250054-A | Reactive polyurethane hot melt adhesive for nylon bonding and preparation method thereof | 广州市白云化工实业有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-113710664-A | JAK1 selective kinase inhibitors | 迪哲(江苏)医药股份有限公司 | 2021-11-26 | — | — | CN | claimed |
| WO-2021076602-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-04-22 | — | — | WO | claimed |
| EP-0828736-A1 | SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-03-18 | — | — | EP | claimed |
| US-5604225-A | DIETETICS; OBESITY | DR. KARL THOMAE GMBH (DE) | 1997-02-18 | — | — | US | claimed |
| EP-0749964-A1 | N-Heterocyclyl biphenyl sulfonamides | ZENECA LIMITED (GB) | 1996-12-27 | — | — | EP | claimed |
| WO-1996040681-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1996-12-19 | — | — | WO | claimed |
| WO-1996038442-A1 | SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-12-05 | — | — | WO | claimed |
| US-5504099-A | STORAGE STABLE AQUEOUS DIURETIC SOLUTION CONTAINING AZOSEMIDE SALT OF ORGANIC AMINE AND BIOCOMPATIBLE ORGANIC SOLVENT | BOEHRINGER MANNHEIM GMBH (DE) | 1996-04-02 | — | — | US | claimed |
| US-5457205-A | Substituted thiazoles useful for treatment of diabetes | DR. KARL THOMAE GMBH (DE) | 1995-10-10 | — | — | US | claimed |
| US-5219852-A | Hypoglycemic agents, treatment of diabetes and obesity | DR. KARL THOMAE GMBH (DE) | 1993-06-15 | — | — | US | claimed |
| EP-0239815-B1 | SUBSTITUTED THIAZOLES AND OXAZOLES, MEDICINES CONTAINING THESE COMPOUNDS AND PROCESS FOR THEIR PREPARATION | Dr. Karl Thomae GmbH (DE) | 1991-07-24 | — | — | EP | claimed |
| US-5026702-A | Enhances physical performance in animals, effective in lowering blood sugar, reducing body fat and lowering atherogenic lipoproteins | DR. KARL THOMAE, GMBH (DE) | 1991-06-25 | — | — | US | claimed |